Mesenchymal stromal cells: tissue engineers and immune response modulators.
until further notice
SourceArchivum Immunologiae et Therapiae Experimentalis, 56, 5, (2008), pp. 325-329
Article / Letter to editor
Display more detailsDisplay less details
Archivum Immunologiae et Therapiae Experimentalis
SubjectNCMLS 1: Immunity, infection and tissue repair; NCMLS 2: Immune Regulation; NCMLS 3: Tissue engineering and pathology; ONCOL 3: Translational research
Mesenchymal stromal cells (MSCs) show significant immune-suppressive properties both in vitro and in vivo. Based on their immune-stealth properties, allogeneic MSCs are used to treat several diseases, for example the injection of MSCs in infarcted heart tissue or their use in bone-cartilage regeneration. The most spectacular treatment was recently described. MSCs were able to down-regulate the severity of graft-versus-host disease, leading to an impressive 20 to 50% increase in the two-year survival of bone marrow transplantation patients. Here the current literature is reviewed to elucidate the different mechanisms involved in these two clinical treatment modalities of MSCs.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.